Home
About Us
Membership
Member Biography

Member Biography

Larry D. Cripe, MD

Larry D. Cripe, M.D.

Phone: (317) 944-0920
Phone: (317) 944-0920, Patient issues/appointments

535 Barnhill Drive
RT 473
Indianapolis, IN 46202

Faculty appointments

Professor of Medicine, Department of Medicine, Division of Hematology/Oncology, IU School of Medicine
Affiliate member

Acute Myeloid Leukemia and the End of Life: An Interview Study of Bereaved Informal Caregivers

Advanced Cancer Decisions: The Roles of Prognostic Understanding and PreferencesIUCRO-0406

Phase Ib study of the safety and efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia: Big Ten Cancer Research Consortium BTCRC-AML17-113BTCRC-AML17-113

Men's Perspectives of the Cancer ExperienceIUCRO-0212

Life and Treatment Goals in People with CancerIUCRO-0255

Development of the Acute Myeloid Leukemia (AML) CARE Road Map: A Goal-Oriented, Collaborative Framework for Critical ConversationsIUSCC-0660

OPTIMIZING THE PERSONAL GOAL EVALUATION EXERCISE, A WEB-BASED RESOURCE TO ENHANCE GOAL-RELATED DELIBERATION AND COMMUNICATION IN CANCER CAREIUSCCC-0767

Acute Myeloid Leukemia and the End of Life: An Interview Study of Bereaved Informal CaregiversIUSCC-0697

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction ChemotherapyA041701

A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)PONATINIB-3001

Optimizing the design and functionality of the CLL Mind Map, an Innovative Digital Decision Aid with A Dynamic Graphical Interactive InterfaceCTO-IUSCCC-0888

Specialty Compared to Oncology Delivered Palliative Care for Patients with Acute Myeloid Leukemia SCOPE-LeukemiaCTO-SCOPE-LEUKEMIA

Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL):CTO-S1925

ONCOLOGY CLINICIANS PERSPECTIVES ON TREATMENT DECISION-MAKING AND THE ACCEPTABILITY AND USABILITY OF THE INTERACTIVE WEB-ENABLED COMMUNICATION RESOURCES OF THE CLL/SLL CARE ROAD MAPCTO-IUSCCC-0915

#ResearchCuresCancer

Support Our Research